Applications are now closed.
SITC-Bristol-Myers Squibb Postdoctoral Cancer Immunotherapy Translational Fellowship
This $200,000, two-year cancer immunotherapy translational fellowship aims to provide support for an individual who has an MD, PhD, or combined MD/PhD degree with a vested interest in furthering the research and translation of cancer immunotherapy.
SITC-Amgen Cancer Immunotherapy in Hematologic Malignancies Fellowship
This $100,000, one-year cancer immunotherapy clinical fellowship aims to provide support for an individual who has an MD (or equivalent) or combined MD/PhD degree with a vested interest in furthering the research and translation of immunotherapeutic approaches for treating patients with hematologic malignancies.
Learn More
SITC-AstraZeneca Immunotherapy in Lung Cancer Clinical Fellowship This $100,000, one-year cancer immunotherapy clinical fellowship aims to provide support for an individual who has an MD (or equivalent) or combined MD/PhD degree with a vested interest in furthering the research and translation of immunotherapeutic approaches for treating patients with lung cancer.
Learn More
SITC-Merck Cancer Immunotherapy Clinical Fellowship
This $100,000, one-year cancer immunotherapy clinical fellowship aims to provide support for an individual who has an MD (or equivalent) or combined MD/PhD degree and a vested interest in furthering the research and translation of cancer immunotherapy.
SITC-Genentech Women in Cancer Immunotherapy Fellowship
This $50,000, one-year fellowship will help support the development of a female immunotherapy expert who has a vested interest in furthering the research and translation of cancer immunotherapy.
SITC’s Holbrook Kohrt, MD, PhD, Cancer Immunotherapy Translational Memorial Fellowship (sponsored by Genentech)
This $50,000, one-year translational fellowship is named after Holbrook Kohrt, MD, PhD, assistant professor at the Stanford University School of Medicine, renowned for his clinical trials research examining novel immunologic approaches and his translational research on novel therapies to enhance anti-tumor immunity. Dr. Kohrt was a member of the Levy Laboratory, which helped develop and test the first U.S. Food and Drug Administration (FDA)-approved antibody against cancer for the treatment of lymphoma in 1997. He started his own laboratory in 2012, and helped develop five novel patented approaches to cancer immunotherapy. This fellowship aims to provide support for an individual who has an MD, PhD, or combined MD/PhD degree with a vested interest in furthering the research and translation of cancer immunotherapy.